RxDoctor Payments Data

Rana Ghauri, MD

Ophthalmology · Houston, TXNPI 1679531123

Payments from drug & device makers

$2,153in general payments, 2019–2025

Across 93 payments — averaging $23.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$857
  • Alcon$163
  • Bausch & Lomb Americas Inc.$135
  • Biotissue Holdings Inc.$129
  • Ocular Therapeutix, Inc.$102
  • Carl Zeiss Meditec USA, Inc.$101
  • plus $666 from 13 others

What the payments were for

  • Food & beverage$2,153100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,153 in reported general payments places this provider in the 50th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$330,332
Medicare patients
778
Services billed
2,795

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine98$128,666
LumiganBimatoprost65$43,222
Cyclosporine46$36,197
Lotemax SmLoteprednol Etabonate140$34,673
ProlensaBromfenac Sodium72$27,317
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol109$25,835
RhopressaNetarsudil Mesylate36$22,630
CombiganBrimonidine Tartrate/Timolol34$16,273
BesivanceBesifloxacin Hcl73$15,983
Latanoprost882$11,322
Brinzolamide39$10,686
Alphagan PBrimonidine Tartrate15$8,438
Prednisolone Acetate157$7,590
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat385$7,413
Travoprost38$6,419

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$857$196,599212 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa, Besivance$66$77,974285 claims
Aerie Pharmaceuticals, Inc.Rhopressa$21$22,63036 claims
AlconSimbrinza$163$5,04821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →